Ac-225-FPI-2265
225Ac-FPI-2265 (225Ac-PSMA-I&T) is another alpha emitter analogue of the marketed [...]
Ac-225-FPI-2059
225Ac-FPI-2059 (225Ac-3BP-227, 225Ac-IPN-01087) is the 225Ac-labeled analogue of 177Lu-IPN-1087, a [...]
Ac-225-DOTA-SP
225Ac-DOTA-SP (225Ac-Substance-P) is developed as local treatment for glioblastoma and [...]
Ac-225-PSMA-617
225Ac-PSMA-617 is the next generation of prostate cancer treatment following [...]
Ac-225-Lintuzumab (Ac-225 Actimab-A™)
225Ac-Lintuzumab (225Ac-Actimab-A™, 225Ac-DOTA-huM195) is the new name of the lead [...]
Ac-225-FPI-1434
225Ac-FPI-1434 (225Ac-FPX-01) is an alpha labeled antibody under development for [...]
Ac-225-DOTAZOL
225Ac-DOTAZOL is a DOTA Zoledronic acid derivative suitable for alphatherapy [...]
Ac-225-DOTATOC
225Ac-DOTATOC is one alpha-labeled analogue of 90Y- and 177Lu-DOTATOC [...]
Ac-225-RYZ101
225Ac-RYZ101 (225Ac-DOTATATE) is the alpha-labeled analogue of 90Y- and 177Lu-DOTATATE. [...]
Ac-225-Rosopatamab
225Ac-Rosopatamab (225Ac-CONV-01-α) is an alpha-radiolabeled monoclonal antibody targeting PSMA [...]